Aliases & Classifications for Variola Major

MalaCards integrated aliases for Variola Major:

Name: Variola Major 12 14 69
Smallpox 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050508
ICD9CM 34 050.0
UMLS 69 C1812609

Summaries for Variola Major

Disease Ontology : 12 A smallpox that results_in severe infection, located in skin, has material basis in Variola virus. The infection results_in_formation_of lesions.

MalaCards based summary : Variola Major, also known as smallpox, is related to smallpox and septic arthritis, and has symptoms including pruritus, fever and exanthema. An important gene associated with Variola Major is TLR3 (Toll Like Receptor 3), and among its related pathways/superpathways are Akt Signaling and IL-2 Pathway. The drugs Vaccines and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include skin, skin and myeloid, and related phenotypes are neoplasm and respiratory system

Related Diseases for Variola Major

Diseases related to Variola Major via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 smallpox 32.3 IFNG IL2
2 septic arthritis 10.3 TLR3 TLR4
3 variola minor 10.2
4 hepatitis e 10.2 IFNG TLR3
5 campylobacteriosis 10.2 IFNG TLR4
6 myositis fibrosa 10.2 IFNG TLR4
7 allergic conjunctivitis 10.2 IFNG TLR3
8 q fever 10.2 IFNG TLR4
9 invasive aspergillosis 10.2 IFNG TLR4
10 melioidosis 10.2 IFNG TLR4
11 orofacial granulomatosis 10.2 CCL3 IFNG
12 typhoid fever 10.2 IFNG TLR4
13 salmonellosis 10.1 IFNG TLR4
14 boutonneuse fever 10.1 IL2 TLR4
15 bone fracture 10.1 IL2 TLR4
16 lymphadenitis 10.1 IFNG TLR4
17 autoimmune myocarditis 10.1 IFNG IL2
18 berylliosis 10.1 IFNG IL2
19 cutaneous leishmaniasis 10.1 IFNG TLR4
20 immune suppression 10.1 IFNG IL2
21 atopic keratoconjunctivitis 10.1 IFNG IL2
22 aspergillosis 10.1 IFNG TLR4
23 clonorchiasis 10.1 IFNG IL2
24 crohn's colitis 10.1 IFNG IL2
25 microscopic colitis 10.1 IFNG IL2
26 chronic active epstein-barr virus infection 10.1 IFNG IL2
27 posterior uveitis 10.1 IFNG IL2
28 intermediate uveitis 10.1 IFNG IL2
29 vulvovaginal candidiasis 10.1 IFNG IL2
30 coccidiosis 10.1 IFNG IL2
31 erythema multiforme 10.1 IFNG IL2
32 hematopoietic stem cell transplantation 10.1 IFNG IL2
33 toxoplasmosis 10.1 IFNG TLR4
34 autoimmune disease of endocrine system 10.1 IFNG IL2
35 lepromatous leprosy 10.1 IFNG IL2
36 hypersensitivity reaction type iv disease 10.1 IFNG IL2
37 acute graft versus host disease 10.1 IFNG IL2
38 chlamydia 10.0 IFNG TLR4
39 pleurisy 10.0 IFNG IL2
40 herpes zoster 10.0 IFNG IL2
41 vernal conjunctivitis 10.0 IFNG IL2
42 helicobacter pylori infection 10.0 IFNG TLR4
43 leprosy 3 10.0 IFNG IL2
44 intestinal disease 10.0 IFNG TLR4
45 mumps 10.0 IFNG IL2
46 tonsillitis 10.0 IFNG IL2
47 tropical spastic paraparesis 10.0 IFNG IL2
48 vaccinia 10.0
49 spondyloarthropathy 10.0 IFNG IL2
50 parasitic protozoa infectious disease 10.0 IFNG IL2

Graphical network of the top 20 diseases related to Variola Major:



Diseases related to Variola Major

Symptoms & Phenotypes for Variola Major

UMLS symptoms related to Variola Major:


pruritus, fever, exanthema

MGI Mouse Phenotypes related to Variola Major:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.26 IFNG IL2 TLR3 TLR4
2 respiratory system MP:0005388 8.92 IFNG IL2 TLR3 TLR4

Drugs & Therapeutics for Variola Major

Drugs for Variola Major (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
2 Antibodies Phase 4,Phase 2,Phase 1
3 gamma-Globulins Phase 4,Phase 2,Phase 1
4 Immunoglobulins Phase 4,Phase 2,Phase 1
5 Immunoglobulins, Intravenous Phase 4,Phase 2,Phase 1
6 Rho(D) Immune Globulin Phase 4,Phase 2,Phase 1
7
Phenol Approved, Experimental Phase 2 108-95-2 996
8
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
9 tannic acid Approved, Nutraceutical Phase 1, Phase 2
10
Mannitol Approved, Investigational Phase 1 69-65-8 6251 453
11 Pharmaceutical Solutions Phase 1
12 Adjuvants, Immunologic Phase 1
13 Anti-Bacterial Agents Phase 1
14 Antibiotics, Antitubercular Phase 1
15 Anti-Infective Agents Phase 1
16 Antiviral Agents Phase 1
17 Interferon Inducers Phase 1
18 interferons Phase 1
19 Krestin Phase 1
20 Protective Agents Phase 1
21 Radiation-Protective Agents Phase 1
22 Keyhole-limpet hemocyanin Phase 1
23 Liver Extracts Phase 1
24 Carboxymethylcellulose Sodium Phase 1
25 Cathartics Phase 1
26 Gastrointestinal Agents Phase 1
27 Laxatives Phase 1
28 Poly I-C Phase 1
29 Poly ICLC Phase 1
30 diuretics Phase 1
31 Natriuretic Agents Phase 1
32 Interferon-gamma

Interventional clinical trials:

(show top 50) (show all 82)

# Name Status NCT ID Phase Drugs
1 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous(VIGIV) Completed NCT01158157 Phase 4
2 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV Recruiting NCT02443623 Phase 4
3 Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
4 Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
5 A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT01144637 Phase 3
6 Safety and Efficacy of CJ-50300 in Healthy Volunteers Completed NCT00607243 Phase 2, Phase 3
7 A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat Completed NCT02474589 Phase 3 tecovirimat
8 IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
9 A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® Active, not recruiting NCT01913353 Phase 3
10 Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Unknown status NCT00103584 Phase 1, Phase 2
11 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection Completed NCT02038881 Phase 2
12 Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Completed NCT00053495 Phase 2
13 A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain) Completed NCT00998543 Phase 2
14 Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults Completed NCT00053482 Phase 2
15 Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine Completed NCT00466245 Phase 2 MVA Smallpox vaccine;Placebo
16 Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults Completed NCT00258947 Phase 2
17 Dressing Preparations for Smallpox Completed NCT00063856 Phase 1, Phase 2
18 APSV in Vaccinia Naive Adults Completed NCT00050518 Phase 2
19 A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
20 A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults Completed NCT00026611 Phase 2
21 A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
22 Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine. Completed NCT00189956 Phase 2
23 Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE® Completed NCT01827371 Phase 2
24 A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects Completed NCT00316524 Phase 2
25 MVA Post-Event: Administration Timing and Boost Study Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
26 Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally Completed NCT00914732 Phase 2
27 Expanded Dryvax Dilution Study in Previously Vaccinated Adults Completed NCT00050505 Phase 2
28 ACAM 3000 MVA at Harvard Medical School Completed NCT00133575 Phase 1, Phase 2
29 High Dose IMVAMUNE® in Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
30 Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients Completed NCT00316589 Phase 2
31 A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis Completed NCT00316602 Phase 2
32 Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients Completed NCT00189904 Phase 1, Phase 2
33 Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Completed NCT00038987 Phase 1, Phase 2
34 Dryvax Dilution-Prev Vacc Adults Completed NCT00032708 Phase 2
35 An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees Completed NCT00686582 Phase 2
36 Evaluation and Treatment of Eye Complications of Vaccinia Vaccination Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
37 Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
38 A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites Completed NCT00890760 Phase 1, Phase 2
39 PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer Completed NCT00005916 Phase 2 rV-PSA;rF-PSA;rV-B7.1
40 Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 Completed NCT00907803 Phase 2 ST-246 400 mg;ST-246 600 mg;Placebo
41 Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Active, not recruiting NCT01266083 Phase 2
42 Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Terminated NCT00053508 Phase 2
43 Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults Completed NCT00079820 Phase 1
44 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax® Completed NCT00042094 Phase 1
45 Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects Completed NCT00189969 Phase 1
46 Human Immune Responses Smallpox Completed NCT00068198 Phase 1
47 Safety and Immunogenicity of CJ-50300 Completed NCT00336635 Phase 1
48 Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects Completed NCT00565929 Phase 1 Placebo
49 A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers Completed NCT00002261 Phase 1
50 Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders Completed NCT00189917 Phase 1

Search NIH Clinical Center for Variola Major

Genetic Tests for Variola Major

Anatomical Context for Variola Major

The Foundational Model of Anatomy Ontology organs/tissues related to Variola Major:

18
Skin

MalaCards organs/tissues related to Variola Major:

38
Skin, Myeloid, Prostate, Eye, Liver

Publications for Variola Major

Articles related to Variola Major:

(show all 27)
# Title Authors Year
1
Remaining questions about clinical variola major. ( 21470458 )
2011
2
Differentiation of Variola major and Variola minor variants by MGB-Eclipse probe melt curves and genotyping analysis. ( 19345728 )
2009
3
Studies of the suitability of fowlpox as a decontamination and thermal stability simulant for variola major. ( 20148078 )
2009
4
Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. ( 17950773 )
2008
5
Structure-assisted discovery of Variola major H1 phosphatase inhibitors. ( 17505108 )
2007
6
Overproduction, purification, and biochemical characterization of the dual specificity H1 protein phosphatase encoded by variola major virus. ( 16793284 )
2006
7
Comparative studies of gamma-interferon receptor-like proteins of variola major and variola minor viruses. ( 8612768 )
1996
8
Analysis of the nucleotide sequence of 23.8 kbp from the left terminus of the genome of variola major virus strain India-1967. ( 8725113 )
1996
9
Functional organization of variola major and vaccinia virus genomes. ( 7483290 )
1995
10
Analysis of the nucleotide sequence of 48 kbp of the variola major virus strain India-1967 located on the right terminus of the conservative genome region. ( 8030365 )
1994
11
Analysis of the complete genome of smallpox variola major virus strain Bangladesh-1975. ( 8184534 )
1994
12
Analysis of the nucleotide sequence of 53 kbp from the right terminus of the genome of variola major virus strain India-1967. ( 7856312 )
1994
13
Nucleotide sequence of 21.8 kbp of variola major virus strain Harvey and comparison with vaccinia virus. ( 1331292 )
1992
14
The pathogenicity of variola virus. A comparison of the growth of standard strains of variola major and variola minor viruses in cell cultures from human embryos. ( 6296226 )
1982
15
Facial scarring after varicella. A comparison with variola major and variola minor. ( 7315828 )
1981
16
Treatment of variola major with adenine arabinoside. ( 162923 )
1975
17
Treatment of variola major with cytosine arabinoside. ( 162924 )
1975
18
Variola major in West Pakistan. ( 5489073 )
1970
19
Chemoprophylaxis and chemotherapy in variola major. II. Therapeutic assessment of CG 662 and Marboran in treatment of variola major in man. ( 5824004 )
1969
20
Chemoprophylaxis and chemotherapy in variola major. I. An assessment of CG 662 and Marboran in prophylaxis of contacts of variola major. ( 5824003 )
1969
21
Assessment of an isothiazole thiosemicarbazone in the prophylaxis of contacts of variola major. ( 4160846 )
1966
22
An isothiazole thiosemicarbazone in the treatment of variola major in man. A controlled clinical trial and laboratory investigations. ( 4160845 )
1966
23
HYBRIDS DERIVED FROM THE VIRUSES OF VARIOLA MAJOR AND COWPOX. ( 14171267 )
1964
24
The chemotherapy of variola major infection. ( 13865851 )
1962
25
The laboratory differentiation between variola major and variola minor. ( 13888357 )
1961
26
Smallpox and alastrim; use of the chick embryo to distinguish between the viruses of variola major and variola minor. ( 13429852 )
1957
27
Haemorrhagic variola major (unvaccinated). ( 14807224 )
1951

Variations for Variola Major

Expression for Variola Major

Search GEO for disease gene expression data for Variola Major.

Pathways for Variola Major

Pathways related to Variola Major according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.11 CCL3 IL2 TLR3 TLR4
2
Show member pathways
12.92 IFNG IL2 TLR3 TLR4
3
Show member pathways
12.47 IFNG IL2 TLR3 TLR4
4
Show member pathways
12.44 IL2 TLR3 TLR4
5
Show member pathways
12.32 IFNG IL2 TLR4
6 12.28 IFNG IL2 TLR3
7
Show member pathways
11.99 IFNG TLR3 TLR4
8
Show member pathways
11.96 IFNG TLR3 TLR4
9 11.9 IFNG TLR3 TLR4
10
Show member pathways
11.76 IL2 TLR3 TLR4
11 11.71 IFNG IL2 TLR4
12
Show member pathways
11.66 CCL3 IFNG IL2
13 11.58 IFNG IL2
14
Show member pathways
11.54 IFNG IL2
15
Show member pathways
11.54 IFNG TLR3 TLR4
16 11.52 IFNG IL2
17
Show member pathways
11.51 CCL3 IFNG IL2 TLR3 TLR4
18 11.5 CCL3 IFNG TLR4
19 11.47 IFNG IL2
20
Show member pathways
11.45 IFNG IL2
21 11.43 CCL3 IFNG TLR4
22
Show member pathways
11.42 IFNG IL2
23 11.34 IFNG IL2
24 11.34 CCL3 IFNG IL2
25 11.31 IFNG TLR4
26 11.3 IFNG IL2
27 11.29 IFNG TLR4
28
Show member pathways
11.27 IFNG IL2 TLR3 TLR4
29 11.26 IFNG IL2
30 11.1 IFNG IL2
31 11.05 IFNG IL2
32 11.01 IFNG IL2
33 10.97 IFNG IL2
34 10.93 TLR3 TLR4
35
Show member pathways
10.89 CCL3 IFNG IL2

GO Terms for Variola Major

Cellular components related to Variola Major according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.02 CCL3 IFNG IL2 TLR3 TLR4

Biological processes related to Variola Major according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.83 CCL3 IFNG IL2
2 inflammatory response GO:0006954 9.82 CCL3 TLR3 TLR4
3 immune response GO:0006955 9.76 CCL3 IFNG IL2 TLR4
4 positive regulation of protein phosphorylation GO:0001934 9.7 IFNG IL2 TLR3
5 cellular response to mechanical stimulus GO:0071260 9.67 TLR3 TLR4
6 positive regulation of gene expression GO:0010628 9.67 CCL3 IFNG TLR3 TLR4
7 apoptotic signaling pathway GO:0097190 9.66 TLR3 TLR4
8 positive regulation of JNK cascade GO:0046330 9.66 TLR3 TLR4
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 IFNG IL2
10 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.65 TLR3 TLR4
11 positive regulation of interleukin-6 production GO:0032755 9.64 TLR3 TLR4
12 toll-like receptor signaling pathway GO:0002224 9.63 TLR3 TLR4
13 positive regulation of interferon-gamma production GO:0032729 9.63 IL2 TLR4
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.62 IFNG TLR4
15 extrinsic apoptotic signaling pathway GO:0097191 9.62 IFNG TLR3
16 positive regulation of B cell proliferation GO:0030890 9.61 IL2 TLR4
17 lipopolysaccharide-mediated signaling pathway GO:0031663 9.61 CCL3 TLR4
18 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.6 TLR3 TLR4
19 positive regulation of interleukin-8 production GO:0032757 9.59 TLR3 TLR4
20 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.58 TLR3 TLR4
21 positive regulation of interferon-beta production GO:0032728 9.58 TLR3 TLR4
22 positive regulation of interleukin-1 beta secretion GO:0050718 9.57 CCL3 TLR4
23 positive regulation of NF-kappaB import into nucleus GO:0042346 9.56 TLR3 TLR4
24 positive regulation of chemokine production GO:0032722 9.55 TLR3 TLR4
25 necroptotic process GO:0070266 9.54 TLR3 TLR4
26 regulation of regulatory T cell differentiation GO:0045589 9.51 IFNG IL2
27 positive regulation of tumor necrosis factor production GO:0032760 9.5 CCL3 TLR3 TLR4
28 I-kappaB phosphorylation GO:0007252 9.49 TLR3 TLR4
29 negative regulation of interleukin-17 production GO:0032700 9.48 IFNG TLR4
30 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.43 TLR3 TLR4
31 positive regulation of interferon-beta biosynthetic process GO:0045359 9.4 TLR3 TLR4
32 positive regulation of interleukin-12 production GO:0032735 9.33 IFNG TLR3 TLR4
33 regulation of dendritic cell cytokine production GO:0002730 9.26 TLR3 TLR4
34 negative regulation of osteoclast differentiation GO:0045671 9.13 CCL3 TLR3 TLR4
35 positive regulation of inflammatory response GO:0050729 8.92 CCL3 IL2 TLR3 TLR4

Molecular functions related to Variola Major according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 CCL3 IFNG IL2

Sources for Variola Major

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....